Skip to main content

Lyon Joseph Douglas's Form 4 filing

Corcept Therapeutics Inc (CORT) · filed Nov 5, 2025

Accession no.
0001193125-25-267548
Filed
Nov 5, 2025
Trade date
Nov 3, 2025
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $368.3K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Lyon Joseph DouglasCIK 0001817838Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 3, 2025Common StockMOption exerciseAcquired+5,000$13.56+$67,80015,277Direct
Nov 3, 2025Common StockSSaleDisposed−5,000$73.65F3−$368,25010,277Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 3, 2025Common StockMOption exerciseDisposed−5,000$0.00$016,571Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range from $73.47 to $73.945 per share. Information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request.

Referenced by the price of 1 transaction in Table I.

Remarks

Chief Accounting & Technology Officer

Read the full filing on SEC EDGAR (opens in a new tab)